The bioprocessing market is preparing for a recovery. The bioprocessing market is about to recover. That's the conclusion from Repligen's (RGEN -1.00%) secondquarter earnings report released earlier in the week and the reason for the stock's 17.7% ascendancy in the week to Friday morning. Repligen and Danaher are seeing budding shoots of recovery A positive view of Repligen's recovery is supported when examining Danaher's recent results, released a week earlier. Danaher is a much larger company selling life ...